Poster podcast
The prognostic performance of PREDICT+ in patients with HER2+ early-stage breast cancer
Autore: Elisa Agostinetto
Institut Jules Bordet and Université Libre de Bruxelles, Belgium; HumanitasClinical and Research Center, IRCCS, Rozzano (MI)
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+/HER2+, node-positive, high-risk early breast cancer
Autore: Sara M. Tolaney
Dana-Farber Cancer Institute, Boston, MA; USA
Clinical trial testing superiority of combination plinabulin and pegfilgrastim versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy: Final results of the phase 3 protective-2 in chemo-induced neutropenia prevention
Autore: Douglas W. Blayney
Stanford Cancer Center, Stanford University, Stanford, CA; USA
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial
Autore: Vladislav Berdunov
PHMR Ltd, London, UK
ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer
Autore: Oleg Gluz
West German Study Group and Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, and University Hospital Cologne, Germany
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
Autore: Giuseppe Curigliano
Istituto Europeo di Oncologia, IRCS, Milano, e Università di Milano
Real-world cost-effectiveness of pertuzumab with trastuzumab + chemo in patients with metastatic breast cancer: A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration
Autore: Wei Fang Dai
Temerty Faculty of Medicine, University of Toronto, Canada
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor degrader, with palbociclib in postmenopausal women with ER+/HER2- metastatic breast cancer
Autore: Sarat Chandarlapaty
Memorial Sloan Kettering Cancer Center, New York, NY; USA
A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients with advanced HR+/HER2-negative breast cancer with visceral or non-visceral disease
Autore: Douglas Yee
Masonic Cancer Center, University of Minnesota, Minneapolis, MN; USA
Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with hormone receptor + (HR+), HER2- metastatic breast cancer not previously treated with a taxane
Autore: Lee Schwartzberg
West Cancer Center and Research Institute, New York, NY; USA
Real-world clinical outcomes on alpelisib in patients with breast cancer and PIK3CA mutations
Autore: Hope Rugo
Div. of Hematology and Oncology, University of California, San Francisco, CA; USA
Metastasectomy versus radiation of secondary sites in stage IV breast cancer
Autore: Nadeem Bilani
Cleveland Clinic Florida, Fort Lauderdale, FL; USA
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
Autore: Seock-Ah Im
Seoul National University Cancer Hospital, Seoul, Rep. of Korea
Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2)
Autore: Shom Goel
Peter MacCallum Cancer Centre, Melbourne, VIC; Australia
Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials
Autore: Mary Kathryn Abel
University of California, School of Medicine and Dept. of Surgery, San Francisco, CA; USA
